Personalised Cancer Vaccine WDVAX shows promise in melanoma

Harvard researchers personalised cancer vaccine, WDVAX, shows promise in advanced melanoma. Tested in 21 patients, it proved safe and activated immune cells, including T-cells, to target tumours. The Phase I trial confirms feasibility for individualised treatment. Future studies will explore combining WDVAX with immunotherapy for enhanced long-term cancer control.